Cargando…
Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients
This study examines whether women with breast cancer, who are adherent and non-adherent to tamoxifen, differ in their perceptions of information received during treatment. This cross-sectional study included women receiving tamoxifen as adjuvant treatment for breast cancer recruited from a teaching...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798421/ https://www.ncbi.nlm.nih.gov/pubmed/29416436 http://dx.doi.org/10.5114/wo.2017.72397 |
_version_ | 1783297850857226240 |
---|---|
author | Cruz, Aline Rodrigues, Aline Ferracini, Amanda Stahlschmidt, Rebeca Silva, Nice Mazzola, Priscila |
author_facet | Cruz, Aline Rodrigues, Aline Ferracini, Amanda Stahlschmidt, Rebeca Silva, Nice Mazzola, Priscila |
author_sort | Cruz, Aline |
collection | PubMed |
description | This study examines whether women with breast cancer, who are adherent and non-adherent to tamoxifen, differ in their perceptions of information received during treatment. This cross-sectional study included women receiving tamoxifen as adjuvant treatment for breast cancer recruited from a teaching hospital specialised in women’s health in the state of São Paulo (Brazil). Women were interviewed and their records were reviewed for socio demographic data and clinical characteristics. We assessed tamoxifen adherence using the Morisky-Green Test, and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire – Information module (EORTC QLQ-INFO25) was used to evaluate the information received by the women. The sample contained 31 women (mean age = 55.4; SD = 11.6 years). According to the Morisky-Green Test, 74.2% of the women had suboptimal tamoxifen adherence. The global score for women’s perceptions of information they received about the treatment and disease was 57.0 ±19.1 on a scale of 0 to 100, and no significant differences in scores were observed between adherents and non-adherents. A high prevalence of suboptimal tamoxifen adherence was observed. We found no significant differences between women with breast cancer who were adherent and non-adherent to tamoxifen. |
format | Online Article Text |
id | pubmed-5798421 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-57984212018-02-07 Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients Cruz, Aline Rodrigues, Aline Ferracini, Amanda Stahlschmidt, Rebeca Silva, Nice Mazzola, Priscila Contemp Oncol (Pozn) Original Paper This study examines whether women with breast cancer, who are adherent and non-adherent to tamoxifen, differ in their perceptions of information received during treatment. This cross-sectional study included women receiving tamoxifen as adjuvant treatment for breast cancer recruited from a teaching hospital specialised in women’s health in the state of São Paulo (Brazil). Women were interviewed and their records were reviewed for socio demographic data and clinical characteristics. We assessed tamoxifen adherence using the Morisky-Green Test, and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire – Information module (EORTC QLQ-INFO25) was used to evaluate the information received by the women. The sample contained 31 women (mean age = 55.4; SD = 11.6 years). According to the Morisky-Green Test, 74.2% of the women had suboptimal tamoxifen adherence. The global score for women’s perceptions of information they received about the treatment and disease was 57.0 ±19.1 on a scale of 0 to 100, and no significant differences in scores were observed between adherents and non-adherents. A high prevalence of suboptimal tamoxifen adherence was observed. We found no significant differences between women with breast cancer who were adherent and non-adherent to tamoxifen. Termedia Publishing House 2017-12-30 2017 /pmc/articles/PMC5798421/ /pubmed/29416436 http://dx.doi.org/10.5114/wo.2017.72397 Text en Copyright: © 2017 Termedia Sp. z o. o. http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Original Paper Cruz, Aline Rodrigues, Aline Ferracini, Amanda Stahlschmidt, Rebeca Silva, Nice Mazzola, Priscila Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients |
title | Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients |
title_full | Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients |
title_fullStr | Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients |
title_full_unstemmed | Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients |
title_short | Analysis of information received during treatment and adherence to tamoxifen in breast cancer patients |
title_sort | analysis of information received during treatment and adherence to tamoxifen in breast cancer patients |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798421/ https://www.ncbi.nlm.nih.gov/pubmed/29416436 http://dx.doi.org/10.5114/wo.2017.72397 |
work_keys_str_mv | AT cruzaline analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients AT rodriguesaline analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients AT ferraciniamanda analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients AT stahlschmidtrebeca analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients AT silvanice analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients AT mazzolapriscila analysisofinformationreceivedduringtreatmentandadherencetotamoxifeninbreastcancerpatients |